BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 1, 2005
View Archived Issues
Biogen Idec, Elan Plummet On Withdrawal Of Tysabri
Two serious adverse events - one ending in death - was enough for Biogen Idec Inc. and Elan Corp. plc to suspend marketing of their multiple sclerosis drug, Tysabri, just three months after FDA approval. (BioWorld Today)
Read More
Tercica Completes Increlex NDA For IGF-1 Deficient Short Stature
Read More
In CF, Smaller Promoter Makes A Better Gene Therapy Vehicle
Read More
With Partner Re-evaluating, Phytopharm Pulls Funding
Read More
Other News To Note
Read More